Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy.
Allergy 70, 715-719 (2015)
While allergen-specific immunotherapy (AIT) is very efficient in hymenoptera venom (HV)-allergic patients, long-term outcome after finishing AIT is not well investigated, especially regarding mechanisms that are suggested to contribute to allergen-specific tolerance. Here, we analyse the Ves v 5-inhibitory activity of sera from wasp venom-allergic patients using the novel cell-free enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) assay. Compared to pre-AIT, sera from patients undergoing AIT displayed an increased ability to inhibit Ves v 5 binding by IgE antibodies. In contrast, this inhibitory activity was reduced in patients having finished AIT 5-12 years ago. Allergen-blocking capacity correlated with serum concentrations of Ves v 5-specific IgG4 which rose during AIT but almost reached pretreatment levels in patients who had stopped AIT more than 5 years ago. These data raise questions about how long allergen tolerance is maintained in AIT-treated HV-allergic patients and suggest that the ELIFAB assay might be an easy-to-use tool assessing long-term tolerance in patients treated with HV-AIT.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Igg ; Allergen-specific Immunotherapy ; Blocking Antibodies ; Enzyme-linked Immunosorbent Facilitated Antigen Binding ; Insect Venom; Long-term Protection; Bee Venom; Pollen Immunotherapy; Antibody-responses; Ige Binding; Inhibition; Severity; Stings
ISSN (print) / ISBN
0105-4538
e-ISSN
1398-9995
Zeitschrift
Allergy
Quellenangaben
Band: 70,
Heft: 6,
Seiten: 715-719
Verlag
Wiley
Verlagsort
Hoboken
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute for Allergy Research (IAF)